|
Automated
Cell’s
Automatedcell
discovery engine includes unique, proprietary human antibody libraries and
proprietary high throughput, functional biological screening to identify
antibody leads and to determine mechanism of action, toxicity and validate
targets at a throughput of 400,000 antibodies per week. We have six issued and
six pending patents.
As a drug
discovery company focused on the development of monoclonal antibody therapeutics
for the treatment of cancer, ACI has developed a target independent approach
where the starting point of drug discovery is the identification of an active
antibody through functional biology, rather than the target. The active
antibody is then used to identify and validate its target in parallel with
secondary screening, saving time and money in driving antibodies to the clinic.
This novel approach to antibody discovery offers several advantages over more
typical genomic/proteomic approaches to target identification and validation: 1)
Targets identified by this method are simultaneously validated and suitable for
antibody therapeutics; 2) Because the approach is function based it is unbiased
with regard to target sequence and offers an opportunity to discover truly novel
targets or assign new previously unrecognized function to new targets, and 3)
Removing target identification and validation from the critical path to the
clinic produces faster INDs.
Automated Cell’s business strategy is directed at building value through
creating a pipeline of monoclonal antibody drug candidates that ACI will both
drive through clinical trials and partner for further development. We
collaborate with pharmaceutical and biotechnology companies to use our
target-independent platform to create drug discovery programs tailored to their
needs. ACI actively out-licenses our targets, therapeutic and diagnostic
antibodies and other aspects of our technology platforms.
Automated Cell’s collaborations include: Abgenix – where we have determined
antibody mechanism of action; Celltech – where we have phenotyped and validated
protein cancer targets; Morphochem – where we optimize small molecule lead
candidates; Precision Therapeutics – where we have out-licensed our cell
phenotyping technology for cancer diagnostics; NIH - who is supporting
technology development with a $2.9 million grant; and technology deals to
increase our capabilities: American Red Cross for antibody library technology,
Acceptys for human monoclonal antibody creation and Strand Genomics for
informatics
Job's in US
Applicants must be a U.S.
resident or currently able to legally work in the U.S.
Automated Cell, Inc.
390 William Pitt Way
Pittsburgh, PA 15238
Tel: 412.826.5250
Fax: 412.826.5215
E-mail:
career@automatedcell.com
Automated Cell, Inc. is an Equal Opportunity Employer
|
